CREB1 is affected by the microRNAs miR-22-3p, miR-26a-5p, miR-27a-3p, and miR-221-3p and correlates with adverse clinicopathological features in renal cell carcinoma.


Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
16 04 2020
Historique:
received: 28 10 2019
accepted: 11 03 2020
entrez: 18 4 2020
pubmed: 18 4 2020
medline: 15 12 2020
Statut: epublish

Résumé

The transcription factor cAMP response element-binding protein (CREB1) has been shown to be involved in diverse biological pathways including the regulation of cell proliferation, apoptosis, cell cycle progression, and metastasis. In this context, aberrant expression of CREB1 and the functional consequences are well investigated in a number of hematopoietic and solid tumors. However, CREB1 expression and underlying control mechanisms are only poorly analyzed in renal cell carcinoma (RCC). The present study confirmed a deregulation of CREB1 protein in the clear cell type of RCC (ccRCC) and analysis of in-house ccRCC cell lines suggested a post-transcriptional control. The combination of miRNA enrichment assay, in silico analysis and molecular biological approaches revealed four novel CREB1-regulating miRNAs, namely miR-22-3p, miR-26a-5p, miR-27a-3p, and miR-221-3p. Categorizing RCC samples as CREB1 negative or positive, respectively, the expression of these miRNAs was found to be inversely correlated with CREB1 protein levels. Analyzing 453 consecutive RCC tumors by immunohistochemistry, weakly negative, but significant correlations of CREB1 with tumor stage and grade, vascular invasion (V1) and lymphovascular invasion (L1) were found. In this respect, ccRCC might differ from other solid tumors like esophageal squamous-cell carcinoma or glioma.

Identifiants

pubmed: 32300145
doi: 10.1038/s41598-020-63403-y
pii: 10.1038/s41598-020-63403-y
pmc: PMC7162877
doi:

Substances chimiques

CREB1 protein, human 0
Cyclic AMP Response Element-Binding Protein 0
MicroRNAs 0

Types de publication

Journal Article Observational Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

6499

Références

Muglia, V. F. & Prando, A. Renal cell carcinoma: histological classification and correlation with imaging findings. Radiol Bras 48, 166–174, https://doi.org/10.1590/0100-3984.2013.1927 (2015).
doi: 10.1590/0100-3984.2013.1927 pubmed: 26185343 pmcid: 4492569
Humphrey, P. A., Moch, H., Cubilla, A. L., Ulbright, T. M. & Reuter, V. E. The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs-Part B: Prostate and Bladder Tumours. Eur Urol 70, 106–119, https://doi.org/10.1016/j.eururo.2016.02.028 (2016).
doi: 10.1016/j.eururo.2016.02.028 pubmed: 26996659
Chow, W. H., Dong, L. M. & Devesa, S. S. Epidemiology and risk factors for kidney cancer. Nat Rev Urol 7, 245–257, https://doi.org/10.1038/nrurol.2010.46 (2010).
doi: 10.1038/nrurol.2010.46 pubmed: 20448658 pmcid: 3012455
Siegel, R. L., Miller, K. D. & Jemal, A. Cancer statistics, 2018. CA Cancer J Clin 68, 7–30, https://doi.org/10.3322/caac.21442 (2018).
doi: 10.3322/caac.21442 pubmed: 29313949
Capitanio, U. & Montorsi, F. Renal cancer. Lancet 387, 894–906, https://doi.org/10.1016/S0140-6736(15)00046-X (2016).
doi: 10.1016/S0140-6736(15)00046-X pubmed: 26318520
Motzer, R. J. et al. Kidney Cancer, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 15, 804–834, https://doi.org/10.6004/jnccn.2017.0100 (2017).
doi: 10.6004/jnccn.2017.0100 pubmed: 28596261
Rini, B. I., Rathmell, W. K. & Godley, P. Renal cell carcinoma. Curr Opin Oncol 20, 300–306, https://doi.org/10.1097/CCO.0b013e3282f9782b (2008).
doi: 10.1097/CCO.0b013e3282f9782b pubmed: 18391630
Yagoda, A., Abi-Rached, B. & Petrylak, D. Chemotherapy for advanced renal-cell carcinoma: 1983-1993. Semin Oncol 22, 42–60 (1995).
pubmed: 7855619
Santoni, M. et al. Immunotherapy in renal cell carcinoma: latest evidence and clinical implications. Drugs Context 7, 212528, https://doi.org/10.7573/dic.212528 (2018).
doi: 10.7573/dic.212528 pubmed: 29899754 pmcid: 5992965
Nickerson, M. L. et al. Improved identification of von Hippel-Lindau gene alterations in clear cell renal tumors. Clin Cancer Res 14, 4726–4734, https://doi.org/10.1158/1078-0432.CCR-07-4921 (2008).
doi: 10.1158/1078-0432.CCR-07-4921 pubmed: 18676741 pmcid: 2629664
Barry, R. E. & Krek, W. The von Hippel-Lindau tumour suppressor: a multi-faceted inhibitor of tumourigenesis. Trends Mol Med 10, 466–472, https://doi.org/10.1016/j.molmed.2004.07.008 (2004).
doi: 10.1016/j.molmed.2004.07.008 pubmed: 15350900
Kaelin, W. G. Jr. Molecular basis of the VHL hereditary cancer syndrome. Nat Rev Cancer 2, 673–682, https://doi.org/10.1038/nrc885 (2002).
doi: 10.1038/nrc885 pubmed: 12209156
Nabi, S., Kessler, E. R., Bernard, B., Flaig, T. W. & Lam, E. T. Renal cell carcinoma: a review of biology and pathophysiology. F1000Res 7, 307, https://doi.org/10.12688/f1000research.13179.1 (2018).
doi: 10.12688/f1000research.13179.1 pubmed: 29568504 pmcid: 5850086
Montminy, M. R. & Bilezikjian, L. M. Binding of a nuclear protein to the cyclic-AMP response element of the somatostatin gene. Nature 328, 175–178, https://doi.org/10.1038/328175a0 (1987).
doi: 10.1038/328175a0 pubmed: 2885756
Zhang, X. et al. Genome-wide analysis of cAMP-response element binding protein occupancy, phosphorylation, and target gene activation in human tissues. Proc Natl Acad Sci USA 102, 4459–4464, https://doi.org/10.1073/pnas.0501076102 (2005).
doi: 10.1073/pnas.0501076102 pubmed: 15753290
Shaywitz, A. J. & Greenberg, M. E. CREB: a stimulus-induced transcription factor activated by a diverse array of extracellular signals. Annu Rev Biochem 68, 821–861, https://doi.org/10.1146/annurev.biochem.68.1.821 (1999).
doi: 10.1146/annurev.biochem.68.1.821
Steven, A. & Seliger, B. Control of CREB expression in tumors: from molecular mechanisms and signal transduction pathways to therapeutic target. Oncotarget 7, 35454–35465, https://doi.org/10.18632/oncotarget.7721 (2016).
doi: 10.18632/oncotarget.7721 pubmed: 26934558 pmcid: 5085243
Cho, E. C., Mitton, B. & Sakamoto, K. M. CREB and leukemogenesis. Crit Rev Oncog 16, 37–46 (2011).
doi: 10.1615/CritRevOncog.v16.i1-2.50
Zhuang, H. et al. Cyclic AMP responsive element-binding protein promotes renal cell carcinoma proliferation probably via the expression of spindle and kinetochore-associated protein 2. Oncotarget 7, 16325–16337, https://doi.org/10.18632/oncotarget.7017 (2016).
doi: 10.18632/oncotarget.7017 pubmed: 26824422 pmcid: 4941317
Wang, X. et al. Cyclic AMP responsive element-binding protein induces metastatic renal cell carcinoma by mediating the expression of matrix metallopeptidase-2/9 and proteins associated with epithelial-mesenchymal transition. Mol Med Rep 15, 4191–4198, https://doi.org/10.3892/mmr.2017.6519 (2017).
doi: 10.3892/mmr.2017.6519 pubmed: 28487942
Huang, S. et al. The Transcription Factor Creb is Involved in Sorafenib-Inhibited Renal Cancer Cell Proliferation, Migration and Invasion. Acta Pharm 68, 497–506, https://doi.org/10.2478/acph-2018-0033 (2018).
doi: 10.2478/acph-2018-0033 pubmed: 31259702
Li, Y. et al. Oncogenic cAMP responsive element binding protein 1 is overexpressed upon loss of tumor suppressive miR-10b-5p and miR-363-3p in renal cancer. Oncol Rep 35, 1967–1978, https://doi.org/10.3892/or.2016.4579 (2016).
doi: 10.3892/or.2016.4579 pubmed: 26796749
Uhlen, M. et al. A pathology atlas of the human cancer transcriptome. Science 357, https://doi.org/10.1126/science.aan2507 (2017).
Braun, J., Misiak, D., Busch, B., Krohn, K. & Huttelmaier, S. Rapid identification of regulatory microRNAs by miTRAP (miRNA trapping by RNA in vitro affinity purification). Nucleic Acids Res 42, e66, https://doi.org/10.1093/nar/gku127 (2014).
doi: 10.1093/nar/gku127 pubmed: 24510096 pmcid: 4005655
Agarwal, V., Bell, G. W., Nam, J. W. & Bartel, D. P. Predicting effective microRNA target sites in mammalian mRNAs. Elife 4, https://doi.org/10.7554/eLife.05005 (2015).
Kruger, J. & Rehmsmeier, M. RNAhybrid: microRNA target prediction easy, fast and flexible. Nucleic Acids Res 34, W451–454, https://doi.org/10.1093/nar/gkl243 (2006).
doi: 10.1093/nar/gkl243 pubmed: 16845047 pmcid: 1538877
Betel, D., Wilson, M., Gabow, A., Marks, D. S. & Sander, C. The microRNA.org resource: targets and expression. Nucleic Acids Res 36, D149–153, https://doi.org/10.1093/nar/gkm995 (2008).
doi: 10.1093/nar/gkm995 pubmed: 18158296
Dweep, H., Sticht, C., Pandey, P. & Gretz, N. miRWalk–database: prediction of possible miRNA binding sites by “walking” the genes of three genomes. J Biomed Inform 44, 839–847, https://doi.org/10.1016/j.jbi.2011.05.002 (2011).
doi: 10.1016/j.jbi.2011.05.002 pubmed: 21605702
Tan, X. et al. The CREB-miR-9 negative feedback minicircuitry coordinates the migration and proliferation of glioma cells. PLoS One 7, e49570, https://doi.org/10.1371/journal.pone.0049570 (2012).
doi: 10.1371/journal.pone.0049570 pubmed: 23185366 pmcid: 3502497
Chien, C. H. et al. Identifying transcriptional start sites of human microRNAs based on high-throughput sequencing data. Nucleic Acids Res 39, 9345–9356, https://doi.org/10.1093/nar/gkr604 (2011).
doi: 10.1093/nar/gkr604 pubmed: 21821656 pmcid: 3241639
Farre, D. et al. Identification of patterns in biological sequences at the ALGGEN server: PROMO and MALGEN. Nucleic Acids Res 31, 3651–3653, https://doi.org/10.1093/nar/gkg605 (2003).
doi: 10.1093/nar/gkg605 pubmed: 12824386 pmcid: 169011
Chhabra, A., Fernando, H., Watkins, G., Mansel, R. E. & Jiang, W. G. Expression of transcription factor CREB1 in human breast cancer and its correlation with prognosis. Oncol Rep 18, 953–958 (2007).
pubmed: 17786359
Jean, D. & Bar-Eli, M. Regulation of tumor growth and metastasis of human melanoma by the CREB transcription factor family. Mol Cell Biochem 212, 19–28 (2000).
doi: 10.1023/A:1007128101751
Seo, H. S. et al. Cyclic AMP response element-binding protein overexpression: a feature associated with negative prognosis in never smokers with non-small cell lung cancer. Cancer Res 68, 6065–6073, https://doi.org/10.1158/0008-5472.CAN-07-5376 (2008).
doi: 10.1158/0008-5472.CAN-07-5376 pubmed: 18676828 pmcid: 3058903
Yamada, T. et al. Akt Kinase-Interacting Protein 1 Signals through CREB to Drive Diffuse Malignant Mesothelioma. Cancer Res 75, 4188–4197, https://doi.org/10.1158/0008-5472.CAN-15-0858 (2015).
doi: 10.1158/0008-5472.CAN-15-0858 pubmed: 26294214
Cerami, E. et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov 2, 401–404, https://doi.org/10.1158/2159-8290.CD-12-0095 (2012).
doi: 10.1158/2159-8290.CD-12-0095 pubmed: 22588877 pmcid: 22588877
Gao, J. et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal 6, pl1, https://doi.org/10.1126/scisignal.2004088 (2013).
doi: 10.1126/scisignal.2004088 pubmed: 23550210 pmcid: 4160307
Mayr, C. Evolution and Biological Roles of Alternative 3′UTRs. Trends Cell Biol 26, 227–237, https://doi.org/10.1016/j.tcb.2015.10.012 (2016).
doi: 10.1016/j.tcb.2015.10.012 pubmed: 26597575
Wang, Y. W., Chen, X., Ma, R. & Gao, P. Understanding the CREB1-miRNA feedback loop in human malignancies. Tumour Biol 37, 8487–8502, https://doi.org/10.1007/s13277-016-5050-x (2016).
doi: 10.1007/s13277-016-5050-x pubmed: 27059735
Kumar, A. P. et al. Akt/cAMP-responsive element binding protein/cyclin D1 network: a novel target for prostate cancer inhibition in transgenic adenocarcinoma of mouse prostate model mediated by Nexrutine, a Phellodendron amurense bark extract. Clin Cancer Res 13, 2784–2794, https://doi.org/10.1158/1078-0432.CCR-06-2974 (2007).
doi: 10.1158/1078-0432.CCR-06-2974 pubmed: 17473212 pmcid: 1948816
Shankar, D. B. et al. The role of CREB as a proto-oncogene in hematopoiesis and in acute myeloid leukemia. Cancer Cell 7, 351–362, https://doi.org/10.1016/j.ccr.2005.02.018 (2005).
doi: 10.1016/j.ccr.2005.02.018 pubmed: 15837624
Wu, D. et al. cAMP-responsive element-binding protein regulates vascular endothelial growth factor expression: implication in human prostate cancer bone metastasis. Oncogene 26, 5070–5077, https://doi.org/10.1038/sj.onc.1210316 (2007).
doi: 10.1038/sj.onc.1210316 pubmed: 17310988
Xie, S. et al. Dominant-negative CREB inhibits tumor growth and metastasis of human melanoma cells. Oncogene 15, 2069–2075, https://doi.org/10.1038/sj.onc.1201358 (1997).
doi: 10.1038/sj.onc.1201358 pubmed: 9366524
Hanna, J., Hossain, G. S. & Kocerha, J. The Potential for microRNA Therapeutics and Clinical Research. Front Genet 10, 478, https://doi.org/10.3389/fgene.2019.00478 (2019).
doi: 10.3389/fgene.2019.00478 pubmed: 31156715 pmcid: 6532434
Jasinski-Bergner, S. et al. Clinical relevance of miR-mediated HLA-G regulation and the associated immune cell infiltration in renal cell carcinoma. Oncoimmunology 4, e1008805, https://doi.org/10.1080/2162402X.2015.1008805 (2015).
doi: 10.1080/2162402X.2015.1008805 pubmed: 26155421 pmcid: 4485830
Chen, P., Li, M., Hao, Q., Zhao, X. & Hu, T. Targeting the overexpressed CREB inhibits esophageal squamous cell carcinoma cell growth. Oncol Rep 39, 1369–1377, https://doi.org/10.3892/or.2017.6167 (2018).
doi: 10.3892/or.2017.6167 pubmed: 29286131
Zhang, J. Q. et al. Prognostic value of coexistence of abnormal expression of micro-RNA-200b and cyclic adenosine monophosphate-responsive element-binding protein 1 in human astrocytoma. Hum Pathol 45, 2154–2161, https://doi.org/10.1016/j.humpath.2014.01.025 (2014).
doi: 10.1016/j.humpath.2014.01.025 pubmed: 25033730
Lu, F., Zheng, Y., Donkor, P. O., Zou, P. & Mu, P. Downregulation of CREB Promotes Cell Proliferation by Mediating G1/S Phase Transition in Hodgkin Lymphoma. Oncol Res 24, 171–179, https://doi.org/10.3727/096504016X14634208142987 (2016).
doi: 10.3727/096504016X14634208142987 pubmed: 27458098
Bukur, J. et al. Functional role of human leukocyte antigen-G up-regulation in renal cell carcinoma. Cancer Res 63, 4107–4111 (2003).
pubmed: 12874014
Geissler, K. et al. Immune signature of tumor infiltrating immune cells in renal cancer. Oncoimmunology 4, e985082, https://doi.org/10.4161/2162402X.2014.985082 (2015).
doi: 10.4161/2162402X.2014.985082 pubmed: 25949868 pmcid: 4368143
Schneider, C. A., Rasband, W. S. & Eliceiri, K. W. NIH Image to ImageJ: 25 years of image analysis. Nat Methods 9, 671–675 (2012).
doi: 10.1038/nmeth.2089
Chen, C. et al. Real-time quantification of microRNAs by stem-loop RT-PCR. Nucleic Acids Res 33, e179, https://doi.org/10.1093/nar/gni178 (2005).
doi: 10.1093/nar/gni178 pubmed: 16314309 pmcid: 1292995
Livak, K. J. & Schmittgen, T. D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25, 402–408, https://doi.org/10.1006/meth.2001.1262 (2001).
doi: 10.1006/meth.2001.1262 pubmed: 11846609
Wotschofsky, Z. et al. Reference genes for the relative quantification of microRNAs in renal cell carcinomas and their metastases. Anal Biochem 417, 233–241, https://doi.org/10.1016/j.ab.2011.06.009 (2011).
doi: 10.1016/j.ab.2011.06.009 pubmed: 21741950
Kozomara, A. & Griffiths-Jones, S. miRBase: annotating high confidence microRNAs using deep sequencing data. Nucleic Acids Res 42, D68–73, https://doi.org/10.1093/nar/gkt1181 (2014).
doi: 10.1093/nar/gkt1181
Zhou, L. et al. Integrated profiling of microRNAs and mRNAs: microRNAs located on Xq27.3 associate with clear cell renal cell carcinoma. PLoS One 5, e15224, https://doi.org/10.1371/journal.pone.0015224 (2010).
doi: 10.1371/journal.pone.0015224 pubmed: 21253009 pmcid: 3013074
Tretbar, U. S., Friedrich, M., Lazaridou, M. F. & Seliger, B. Identification of Immune Modulatory miRNAs by miRNA Enrichment via RNA Affinity Purification. Methods Mol Biol 1913, 81–101, https://doi.org/10.1007/978-1-4939-8979-9_6 (2019).
doi: 10.1007/978-1-4939-8979-9_6 pubmed: 30666600
Team, R. C. R: A Language and environment for statistical computing. (2019).
Kassambara, A., Kosinski, M. & Biecek, P. Drawing Survival Curves using ‘ggplot2’. http://www.sthda.com/english/rpkgs/survminer/ (2019).

Auteurs

Michael Friedrich (M)

Institute for Medical Immunology, Martin Luther University Halle-Wittenberg, 06112, Halle (Saale), Germany.

Nadine Heimer (N)

Institute for Medical Immunology, Martin Luther University Halle-Wittenberg, 06112, Halle (Saale), Germany.

Christine Stoehr (C)

Institute of Pathology, University Erlangen-Nürnberg, 91054, Erlangen, Germany.

André Steven (A)

Institute for Medical Immunology, Martin Luther University Halle-Wittenberg, 06112, Halle (Saale), Germany.

Sven Wach (S)

Institute of Urology, University Erlangen-Nürnberg, 91054, Erlangen, Germany.

Helge Taubert (H)

Institute of Urology, University Erlangen-Nürnberg, 91054, Erlangen, Germany.

Arndt Hartmann (A)

Institute of Pathology, University Erlangen-Nürnberg, 91054, Erlangen, Germany.

Barbara Seliger (B)

Institute for Medical Immunology, Martin Luther University Halle-Wittenberg, 06112, Halle (Saale), Germany. barbara.seliger@uk-halle.de.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH